Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
HOWL
Upturn stock ratingUpturn stock rating

Werewolf Therapeutics Inc (HOWL)

Upturn stock ratingUpturn stock rating
$1.32
Last Close (24-hour delay)
Profit since last BUY-17.02%
upturn advisory
SELL
SELL since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: HOWL (1-star) is a SELL. SELL since 5 days. Profits (-17.02%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $7.5

1 Year Target Price $7.5

Analysts Price Target For last 52 week
$7.5 Target price
52w Low $0.6
Current$1.32
52w High $4.18

Analysis of Past Performance

Type Stock
Historic Profit -42.98%
Avg. Invested days 21
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 59.23M USD
Price to earnings Ratio -
1Y Target Price 7.5
Price to earnings Ratio -
1Y Target Price 7.5
Volume (30-day avg) 6
Beta 0.64
52 Weeks Range 0.59 - 4.18
Updated Date 08/15/2025
52 Weeks Range 0.59 - 4.18
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.64

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date 2025-08-14
When -
Estimate -0.47
Actual -0.4

Profitability

Profit Margin -
Operating Margin (TTM) -6511.2%

Management Effectiveness

Return on Assets (TTM) -32.66%
Return on Equity (TTM) -82.81%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4205212
Price to Sales(TTM) 51.82
Enterprise Value 4205212
Price to Sales(TTM) 51.82
Enterprise Value to Revenue 3.68
Enterprise Value to EBITDA 0.57
Shares Outstanding 44873600
Shares Floating 26687255
Shares Outstanding 44873600
Shares Floating 26687255
Percent Insiders 6.07
Percent Institutions 57.4

ai summary icon Upturn AI SWOT

Werewolf Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing transformative cancer therapeutics. Founded in 2017, they leverage their proprietary PREDATORu2122 protein engineering platform to design conditionally activated, non-replicating ADARed cytokine therapeutics.

business area logo Core Business Areas

  • Drug Development: Focuses on the research, development, and clinical trials of novel ADARed cytokine therapeutics for cancer treatment.
  • PREDATORu2122 Platform: This proprietary platform is used to engineer cytokines that are activated specifically in the tumor microenvironment.
  • Partnerships and Collaborations: Exploring strategic partnerships and collaborations to expand the development and commercialization of their therapies.

leadership logo Leadership and Structure

The leadership team consists of experienced executives in drug development and biotechnology. The organizational structure is typical of a clinical-stage biopharmaceutical company.

Top Products and Market Share

overview logo Key Offerings

  • ATN-103 (iADAREd IL-2): The company's lead clinical candidate is iADAREd IL-2, designed to selectively activate IL-2 in the tumor microenvironment to stimulate anti-tumor immunity. Currently in Phase 1 clinical trials. Competitors developing similar immunotherapies include companies focusing on IL-2 and other cytokine-based treatments.
  • ATN-605 (iADAREd IL-15): A pre-clinical candidate, iADAREd IL-15, is another tumor-selective immunotherapy designed to activate IL-15 in the tumor microenvironment. Competitors are developing similar immunotherapies, including those targeting the IL-15 pathway.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry, particularly the oncology sector, is highly competitive and rapidly evolving. The demand for innovative cancer therapies is strong.

Positioning

Werewolf Therapeutics is positioned as a company developing novel immunotherapies using its proprietary PREDATOR platform to create tumor-selective cytokines. This differentiation aims to improve efficacy and reduce toxicity compared to traditional cytokine therapies.

Total Addressable Market (TAM)

The global oncology market is estimated to be worth hundreds of billions of dollars. Werewolf Therapeutics is focused on a sub-segment of this market - cytokine-based immunotherapies - representing a multi-billion dollar opportunity. The company's positioning targets a specific niche in the oncology market, leveraging its proprietary technology.

Upturn SWOT Analysis

Strengths

  • Proprietary PREDATOR platform for tumor-selective cytokine development
  • Experienced leadership team
  • Promising preclinical and early clinical data
  • Focus on a high-demand area (oncology immunotherapies)

Weaknesses

  • Limited clinical data
  • Reliance on a single technology platform
  • Cash burn rate typical of clinical-stage biotechs
  • Subject to regulatory approval risks

Opportunities

  • Positive clinical trial results leading to partnerships and funding
  • Expansion of the PREDATOR platform to other targets
  • Potential for breakthrough therapy designation or fast track approval
  • Acquisition by a larger pharmaceutical company

Threats

  • Clinical trial failures
  • Competition from established pharmaceutical companies
  • Regulatory hurdles and delays
  • Economic downturn impacting funding availability

Competitors and Market Share

competitor logo Key Competitors

  • NKTR
  • ALKS
  • AGEN
  • MRTX

Competitive Landscape

Werewolf Therapeutics competes with other companies developing immunotherapies, particularly those focused on cytokines. Its PREDATOR platform offers a potential competitive advantage in terms of tumor selectivity and reduced toxicity.

Growth Trajectory and Initiatives

Historical Growth: Growth is primarily driven by progress in clinical development and pipeline expansion.

Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization success. Analyst estimates vary.

Recent Initiatives: Recent initiatives include advancing ATN-103 through Phase 1 clinical trials and progressing preclinical programs.

Summary

Werewolf Therapeutics is a clinical-stage biotech company focusing on novel cancer immunotherapies. The company's proprietary PREDATOR platform is a key strength, enabling the development of tumor-selective cytokines. Clinical trial outcomes and regulatory approvals are major factors influencing its future success. Competition is intense, and the company faces financial risks typical of early-stage biotechs.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Werewolf Therapeutics Inc. website
  • SEC filings
  • Industry reports
  • Analyst reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data is based on publicly available information and is subject to change. Market share data is estimated. Invest at your own risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Werewolf Therapeutics Inc

Exchange NASDAQ
Headquaters Watertown, MA, United States
IPO Launch date 2021-04-30
Founder, CEO, President, Secretary & Director Dr. Daniel J. Hicklin Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 46
Full time employees 46

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.